Home
Company
Core
Product
News
Contact Us
Related links
Language
NEWS
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update

Review of pluripotent stem cell-derived therapies in clinical trials, focusing on progress, safety, and efficacy data since 2025.

learn more
Top 10 Breakthroughs in Stem Cell Therapy in 2025 | *Cell Stem Cell*

*Cell Stem Cell* | Top 10 Breakthrough Advances in Stem Cell Therapy in 2025, Including Clinical Trial Progress of Pluripotent Stem Cell–Derived Therapies and Treatments for Ocular, Neurological, and Cardiac Diseases

learn more
About US
Neo Bio International Pte., Ltd.
Neo Bio International Ltd is a wholly-owned subsidiary of Singapore - Neo Bio International Pte., Ltd, invested by British Cayman Islands - Neo Bio International Holding Inc. with a registered capital of 10 million yuan, and settled in Xiangjiang New Area in December 2025. The company mainly engages in cross-border sales of daily necessities, cosmetics, health food, etc., providing comprehensive cross-border e-commerce solutions such as global logistics, warehousing, and payment, covering B2B and B2C models, and deeply cultivating markets in Europe, America, Southeast Asia, and other regions. We plan to build a production base by the end of 2026, focusing on areas such as gene editing and industrialization of cell culture. Adhering to the concept of "excellent quality, favorable price", we aim to link global biotechnology resources and achieve two-way circulation of high-quality goods from China and abroad.
ADDRESS ：7500A BEACH ROAD, #04-307, THEPLAZA,SINGAPORE 199591
Email: service@neobio-technology.com
© 2025~2026, Universal Biocells Pte.Ltd, All Rights Reserved
Powerby Feedback Follow Data
Back to Top